The recent approval of several swine flu vaccines by top pharmaceutical companies will benefit industries associated with the swine flu virus.

Roche share price hasn’t exceeded the 20% return since the first swine flu symptoms were reported in Mexico in April 2009, a clear indication that Tamiflu is not the solution to the swine flu pandemic. Relenza, produced by GlaxoSmithKline, is also reporting the same ineffective results primarily over children under 12.

The 500% plus increase of Novavax share price since the swine flu symptoms invaded the media, puts this company at the peak of the high-yielding list of stocks to watch, but also, at the highest risk. For how much longer will Novavax Pharmaceuticals be able to sustain the share price?

Novartis Pharma emerged as one of the front runners of the swine flu vaccine race when the first experimental batch was released in early June. However, Novartis vaccines don’t represent even a quarter of the earnings so an achievement in the swine flu vaccine shouldn’t create a significant impact over Novartis share price.

BioSante´s innovative vaccine adjuvant and delivery system, BioVant, can increase the effectiveness of flu vaccines, including for the new swine flu vaccine. However, these results are based on per-clinical trials and BioSante’s achievements in this area are still on a research and development level.